Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kangai No.2
- Development stage
- Unknown
- Lead developer
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kangai No.2 is a Traditional Chinese Medicine (TCM) herbal formula developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine, specifically for the treatment of colorectal cancer (CRC). It is primarily utilized as an adjuvant therapy to prevent post-operative recurrence and metastasis in patients with CRC. The formula is composed of several medicinal herbs, including *Astragalus membranaceus*, *Atractylodes macrocephala*, and *Scutellaria barbata*, which are thought to work synergistically to inhibit tumor progression. Research indicates that Kangai No.2 exerts its anti-cancer effects by modulating the tumor microenvironment, inhibiting the Wnt/beta-catenin signaling pathway, and suppressing epithelial-mesenchymal transition (EMT). It is often administered alongside standard chemotherapy to enhance therapeutic efficacy and mitigate treatment-related toxicity.
- Brand names
- Kangai No.2 Prescription
- Other names
- Kangai II formulaKangai No. 2 decoctionKangai No. 2 granules
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on Kangai No.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kangai No.2.